Hear about the extended overall survival and additional outcomes for patients with 1L HER2- GC/GEJC and PD-L1 scores ≥1%1
Watch this video to learn about the clinical trial results with TEVIMBRA + chemotherapy vs placebo + chemotherapy
1L, first line; GC, gastric cancer; GEJC, gastroesophageal junction cancer; HER2, human epidermal growth factor receptor 2; PD-L1, programmed death ligand 1.
Reference: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2026.